Kou’s team engineered L-carnitine-conjugated nanoparticles (LC-PLGA NPs) that exploit the OCTN2 overexpression on brain endothelial and glioma cells for enhanced BBB permeability and targeted glioma cell internalization [56]. The gene discussed is SLC22A5; the disease is central nervous system cancer.